Torrent Pharmaceuticals posts Q1FY23 consolidated PAT Rs. 354 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.

Torrent Pharmaceuticals consolidated PAT at Rs 249 cr

Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.

Torrent Pharmaceuticals Q1FY22 consolidated PAT up at Rs. 330 Cr

The company posted net profit of Rs.321 crores for the period ended June 30, 2020.

Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr

The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore

Lyka Labs secures Indian patent for Pregabalin Gel 8%

Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain

Torrent Pharma inks agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands

The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market

Akums appoints Amrut Medhekar as CEO - CDMO Business

e brings over 27+ years of rich pharmaceutical experience

Torrent inks licensing agreement with Takeda to commercialize its novel gastrointestinal drug in India

Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders

Ipca appoints Hitesh Kumar Maheshwari as President – R&D (Formulations)

He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya